Extract from the Register of European Patents

Citations: EP1485127

Cited inSearch
Type:Patent literature
Publication No.:US2001046496  [X]
 (BRETTMAN LEE R ET AL) [X] 19-22 * figures 7,9; examples 1,2 *
Type:Non-patent literature
Publication information:[DXY]  - TUBRIDY N ET AL, "The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.", NEUROLOGY. 11 AUG 1999, (19990811), vol. 53, no. 3, ISSN 0028-3878, pages 466 - 472, XP008050557 [DX] 1-18,23-37,42-54,57,58 * the whole document * [Y] 38,41
Type:Non-patent literature
Publication information:[DXY]  - GORDON FIONA H ET AL, "A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease", GASTROENTEROLOGY, (200108), vol. 121, no. 2, ISSN 0016-5085, pages 268 - 274, XP008050508 [DX] 1-18,23-37,42-54,57,58 * the whole document * [Y] 39,40,55,56
DOI: http://dx.doi.org/10.1053/gast.2001.26260
Type:Non-patent literature
Publication information:[X]  - GORDON F H ET AL, "TREATMENT OF ACTIVE ULCERATIVE COLITIS WITH A RECOMBINANT HUMANISEDANTIBODY TO ALPHA4 INTEGRIN (ANTEGREN TM)", GASTROENTEROLOGY, W.B.SAUNDERS COMPANY, PHILADELPHIA, US, (199904), vol. 116, no. 4, PART 2, ISSN 0016-5085, page A726, XP001024675 [X] 1-18,23-37,42-54,57,58 * the whole document *
Type:Non-patent literature
Publication information:[X]  - GORDON FIONA H ET AL, "Randomised double-blind placebo-controlled trial of recombinant humanised antibody to alpha4 integrin (Antegren(R)) in active Crohn's disease", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, (199904), vol. 116, no. 4 PART 2, ISSN 0016-5085, page A726, XP002179755 [X] 1-18,23-37,42-54,57,58 * the whole document *
Type:Non-patent literature
Publication information:[X]  - SHEREMATA W A ET AL, "A PLACEBO-CONTROLLED, SAFETY, TOLERABILITY DOSE ESCALATION, PK STUDY OF VARIOUS DOSES OF INTRAVENOUS ANTEGREN IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, (199804), vol. 50, no. 4, SUPPL 4, ISSN 0028-3878, pages A63 - A64, XP001024677 [X] 1-18,23-37,42-54,57,58 * the whole document *
Type:Non-patent literature
Publication information:[Y]  - ROBINSON M, "OPTIMIZING THERAPY FOR INFLAMMATORY BOWEL DISEASE", AMERICAN JOURNAL OF GASTROENTEROLOGY, NEW YORK, NY, US, (199712), vol. 92, no. 12, ISSN 0002-9270, pages 12S - 17S, XP000893013 [Y] 38-40,55,56 * the whole document *
Type:Non-patent literature
Publication information:[Y]  - ANDERSSON PETER-BRIAN ET AL, "Glucocorticosteroid therapy for multiple sclerosis: A critical review", JOURNAL OF THE NEUROLOGICAL SCIENCES, (19980918), vol. 160, no. 1, ISSN 0022-510X, pages 16 - 25, XP002350553 [Y] 38,41 * the whole document *
DOI: http://dx.doi.org/10.1016/S0022-510X(98)00116-6
Type:Non-patent literature
Publication information:[Y]  - GOODKIN D E, "Experimental therapies for multiple sclerosis: current status", CLEVELAND CLINIC JOURNAL OF MEDICINE, CLEVELAND, OH, US, (199202), vol. 59, no. 1, ISSN 0891-1150, pages 63 - 74, XP002092153 [Y] 38,41 * the whole document *
Type:Non-patent literature
Publication information:[Y]  - BRYANT J ET AL, "Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?", JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, (200105), vol. 70, no. 5, ISSN 0022-3050, pages 574 - 579, XP002350554 [Y] 38,41 * the whole document *
DOI: http://dx.doi.org/10.1136/jnnp.70.5.574
Cited inInternational search
Type:Patent literature
Publication No.:US5932214  [Y]
 ;
Type:Patent literature
Publication No.:US5840299  [Y]
 ;
Type:Non-patent literature
Publication information:[Y]  - TILLEY ET AL., "VLA-4 Antagonists", DRUGS OF THE FUTURE, (2001), vol. 26, no. 10, pages 985 - 998, XP002975527
DOI: http://dx.doi.org/10.1358/dof.2001.026.10.858716